Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is being trialed for possible therapeutic use in COVID-19.

In an abstract published in October, 2020, fluvoxamine showed promise in a randomized, placebo-controlled trial of 152 COVID-19 positive outpatients:

152 participants were randomized in the modified intention to treat group. No patients (0/80, 0%) in the fluvoxamine group clinically deteriorated, compared to 8.3% (6/72) in the placebo group (logrank chi-square 6.8, p=0.009).

Mechanism of possible benefit?

Sigma-1 receptor

Mechanisms of potential benefit in COVID-19 may include sigma-1 receptor agonism.  See "Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor" and "Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis".


An observational study of 7,345 hospitalized COVID-19 patients hinted at possible benefit of prior SSRI usage.

See also